Lifeloc Technologies, Inc. (OTC: LCTC), a leader in breath alcohol testing devices, has released its financial results for the fiscal year ending December 31, 2025. The company reported a revenue growth of 6%, reaching $9.027 million compared to $8.538 million in 2024. However, Lifeloc also reported a net loss of $2.470 million, or $0.90 per diluted share, which is a significant increase from the previous year's loss of $1.053 million, or $0.41 per diluted share. This increase in loss was primarily attributed to a one-time non-cash charge related to the valuation allowance for deferred taxes, which rose to $1.738 million in 2025 from $187 thousand in 2024. Despite the increased losses, the company noted that its core product line remains strong, with expectations for continued market penetration and growth in the alcohol detection sector. The company is also advancing its SpinDetect™ Centrifugal Drug Analyzer, which aims to address the growing need for rapid drug testing solutions. Lifeloc's management expressed confidence in the long-term potential of their product offerings, despite the current financial challenges. The company continues to manage R&D spending in alignment with cash generated from its core business, indicating a cautious but strategic approach to future growth.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.